报价延迟最少15分钟:2026/10/18 23:07 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.94 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-17.37/-4.69
|
|
企业价值
197.91M
|
| 资产负债 |
|
每股账面净值
-6.23
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
102.48M
|
|
每股收益
3.43
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others. |
